Numinus Wellness Provides Corporate Update - strategic shift to clinical trials and practitioner training, plus audit and TSX delisting review

Numinus Wellness provides a corporate update covering its operational transformation and regulatory or listing-status progress. Over the past year, the company streamlined operations, sold its U.S. wellness clinics, wound down certain non-operating subsidiaries, and changed leadership, shifting focus to two core segments: a clinical trial site network and a practitioner training platform. Numinus says its clinical trial sites continue supporting psychedelic drug development and have participated in more than twenty clinical studies, while its training programs have reached more than 2,500 practitioners, including over 800 research therapists trained for psychedelic clinical trials. The company also describes expanding training in 2025 to support drug development sponsors. On compliance and capital markets, Numinus reports an in-progress 2025 audit after a recent auditor change, which it says is needed to file financial statements, resolve a British Columbia Securities Commission cease trade order, and respond to a Toronto Stock Exchange delisting review initiated in November 2025. It also notes it did not hold its 2025-year annual general meeting by the TSX deadline and intends to schedule it after audit completion and CTO-related progress.